Analysts Rally Behind Versigent After Q1 Beat

VGNT enters the week riding a 33% one-month gain, and the Street is scrambling to keep up with the stock.

Three separate analyst teams raised their price targets on Wednesday alone — the clearest sign yet that the buy side is digesting a strong earnings print with more conviction than anticipated. UBS lifted its target to $49, up from $43, while TD Cowen moved to the same figure from $47. Wells Fargo pushed its Overweight target to $42 from $35 — a 20% revision. All three maintained their existing positive ratings rather than upgrading from neutral, meaning the real story here is target inflation, not a change in qualitative stance. The mean target across the analyst base now lands at $45.63 — implying roughly 22% upside from the current close of $37.50. The coverage base is also fresh: Deutsche Bank initiated at Hold with a $35 target just last week, and both UBS and Wells Fargo only opened coverage in mid-April. The Street is still forming its view on this name.

The lending market tells a notably relaxed story about short-side conviction. Borrow availability is extraordinarily loose at over 4,100% of short interest — meaning there are more than 41 shares available to borrow for every one already shorted. Cost to borrow has drifted back to just 0.57%, having collapsed from a spike above 23% in early April. That spike now looks like a brief episode of borrow stress, possibly tied to the stock's listing activity or an early short burst, not a sustained squeeze. SI as a percentage of free float measures 2.3%, and while shares short ticked up about 5.7% on the week to roughly 1.65 million, the ORTEX short score of 29.3 out of 100 is firmly in the low-pressure range. None of this signals a crowded short or an active short squeeze thesis.

Options positioning also leans heavily bullish, which fits the broader tape. The put/call ratio has collapsed to 0.027 — near the bottom of its 52-week range of 0.0 to 0.11. For context, the ratio was above 0.10 as recently as April 29-30, around the time of the earnings announcement. The swift rotation toward calls since then reflects the post-print reset in sentiment: buyers of upside, not hedgers. Borrow availability and options lean in the same direction — this is not a name where traders are paying up to protect against a reversal.

Valuation remains cheap for what the company is generating. The P/E multiple has expanded to roughly 5.4x as the stock has re-rated, but that is still modest against an EV/EBITDA of approximately 4.0x and revenue of $9.3 billion. Net income for the period came in near $415 million, with operating cash flow of $514 million. For an automotive parts and equipment business of this size, the multiples suggest the market is still applying a meaningful discount — whether for sector cyclicality, the newness of the coverage base, or uncertainty about the trajectory of margins. The stock's P/B has climbed to 5.7x, up nearly 0.4x on the week, reflecting the re-rating in progress.

Institutional ownership is still being established. Vanguard holds the largest disclosed stake at nearly 15% of shares outstanding, followed by BlackRock at just under 11%. All top holders appear to have entered as initial positions — every change figure matches the shares held exactly — consistent with a name that went public or restructured recently and is still in the process of being built into institutional portfolios. The holder count of just 23 known institutions underscores how early-stage the ownership base remains.

What to watch next: whether the analyst upgrades that have so far lagged the price action — Deutsche Bank's Hold at $35 is already 6% below the current price — begin to shift as consensus firms up, and whether the expanding institutional footprint attracts larger active managers into what is currently a passive-heavy, lightly-covered name.